RGLS | Regulus Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.4550 - 1.6201
52 Week Range	1.0800 - 3.79
Beta	1.64
Implied Volatility	358.23%
IV Rank	57.11%
Day's Volume	356,857
Average Volume	341,790
Shares Outstanding	65,500,100
Market Cap	100,870,154
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-10-09

Valuation
Profitability
Growth
Health
P/E Ratio	-1.51
Forward P/E Ratio	N/A
EPS	-1.02
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	32
Country	USA
Website	RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

RGLS's peers: INFI, TENX, VSTM, PULM, CLRB

*Chart delayed

Analyzing fundamentals for RGLS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak. For more detailed analysis please see RGLS Fundamentals page.

Watching at RGLS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RGLS Technicals page.